A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial

OBJECTIVES: SARS-CoV2 infection leads to a concomitant pulmonary inflammation. This inflammation is supposed to be the main driver in the pathogenesis of lung failure (Acute Respiratory Distress Syndrome) in COVID-19. Objective of this study is to evaluate the efficacy and safety of a single dose tr...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Trials
Päätekijät: Rilinger, Jonathan, Kern, Winfried V., Duerschmied, Daniel, Supady, Alexander, Bode, Christoph, Staudacher, Dawid L., Wengenmayer, Tobias
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2020
Aiheet:
Letter
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7267747/
https://ncbi.nlm.nih.gov/pubmed/32493514
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-020-04447-3
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia